Abstract
Novartis will pay Voyager Therapeutics $54 million, plus potential future payments, for an option to license adeno-associated virus (AAV) capsids, or shells, for delivering gene therapies. Novartis markets Zolgensma, a gene therapy for spinal muscular atrophy that is delivered with AAVs. But Voyager says conventional AAVs require high doses that can be toxic. The firm says AAV capsids discovered with its Tracer platform can better target desired tissue and cell types.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
